NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000002427

Registered date:14/09/2009

Evaluation of efficacy to combine radiofrequency ablation therapy and intrahepatic arterial infusion of DDP-H for hepatocellular carcinoma

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedHepatocellular carcinoma
Date of first enrollment2009/09/01
Target sample size120
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Radiofrequency ablation therapy Radiofrequency ablation therapy + intrahepatic arterial infusion of DDP-H

Outcome(s)

Primary Outcome1) Primary endpoint, the time when a classical HCC is confirmed by several imaging modalities in the liver except for the vicinity to the RFA area. 2) Secondary endpoint, allover survival
Secondary OutcomeTumor markers of AFP, DCP and other serum biochemistries.

Key inclusion & exclusion criteria

Age minimum15years-old
Age maximum80years-old
GenderMale and Female
Include criteria
Exclude criteria1) Severe allergic history for iodine and platinum drug 2) Pregnant, possibility of pregnancy, or feeding a baby 3) Vascular involvement Vp3, Vv3 or more 4) Under interferon therapy 5) Other factors that a responsible doctor judged to be unsuitable

Related Information

Contact

public contact
Name Akihiko Ohsaki
Address 1-757 Asahi-machi, Chuo-ku, Niigata, Niigata 951-8122, Japan Japan
Telephone 025-227-2207
E-mail tm98020ao-nii@umin.ac.jp
Affiliation Niigata Hepatocellular Carcinoma Therapy Study Group Excutive office
scientific contact
Name Takeshi Suda
Address 1-754 Asahi-machi, Chuo-ku, Niigata, Niigata 951-8122, Japan Japan
Telephone 025-223-6161
E-mail tspitt@med.niigata-u.ac.jp
Affiliation Niigata University Graduate School of Medical and Dental Sciences Department of Gastroenterology & Hepatology